Higher Versus Lower Protein Delivery in Critically Ill Patients: A Systematic Review and Bayesian Meta-Analysis
Authors' conclusion
There is a considerable probability of an increased mortality risk with higher protein delivery in critically ill patients, although a clinically beneficial effect cannot be completely eliminated based on the current data.
Study context
- Population
- Adult critically ill patients receiving enteral and/or parenteral protein
- Participants
- 4,164 patients · 22 RCTs
- Comparison
- Higher vs lower protein delivery
- Outcome
- Mortality
Methodological detailsBayesian hierarchical random-effects models, vague priors, PRISMA 2020, Risk of bias assessed with risk of bias 2.0 tool
- Bayesian hierarchical random-effects models
- Vague priors
- PRISMA 2020
- Risk of bias assessed with risk of bias 2.0 tool
Pooled result
As reported in the abstract
- Median RR for mortality, higher vs lower protein delivery
- 1.01 (95% CrI 0.84-1.16)
- Posterior probability of any mortality benefit from higher protein delivery (RR < 1.00)
- 43.6%
- Posterior probability of any mortality harm from higher protein delivery (RR > 1.00)
- 56.4%
- Probability of 1% mortality reduction by higher protein delivery (RR < 0.99)
- 38.7%
- Probability of 5% mortality reduction by higher protein delivery (RR < 0.95)
- 22.9%
- Probability of 1% mortality increase (RR > 1.01)
- 51.5%
- Probability of 5% mortality increase (RR > 1.05)
- 32.4%
Original publication
Higher Versus Lower Protein Delivery in Critically Ill Patients: A Systematic Review and Bayesian Meta-Analysis. Crit Care Med. Published 27 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →